scholarly journals Description of Visfatin Adipokine and its Roles on Inflammation and Coronary Heart Disease

2021 ◽  
Vol 2 (1) ◽  
pp. 10-14
Author(s):  
Assist. Prof. Dr. Wijdan Rajh Hamza Al-Kraity ◽  
Ali Hussein Faisal ◽  
Ali Nabeel Khaleel ◽  
Mahmoud Tuama Naeaam ◽  
Ali Sattar Jabar
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Oxygen Demand ◽  
Myocardial Oxygen Demand ◽  
Nicotinamide Phosphoribosyltransferase ◽  
Glucose Levels ◽  
Atherosclerotic Lesions ◽  
Cardiac Blood ◽  
Key Enzyme ◽  
Visceral Adipose

Coronary heart disease (CHD) is a generic designation for a group of related syndromes resulting from myocardial ischemia – an imbalance between cardiac blood supply (perfusion) and myocardial oxygen demand. Visfatin (VF)  is a recently discovered adipokine with different functions, Visfatin is mainly found in visceral adipose tissue and mimics insulin in lowering plasma glucose levels and, Visfatin emerges as a player in the development and progression of atherosclerotic lesions by directly promoting smooth muscle cell proliferation, Aberrant angiogenesis is now considered a feature of the atherogenic process in both coronary and carotid diseases. This adipokine was previously known as a pre-B-cell colony-enhancing factor   (PBEF) or  Nicotinamide phosphoribosyltransferase (NAmPRTase or Nampt) an enzyme that in humans is encoded by the NAMPT gene  and demonstrated to be an intracellular protein with a key enzyme role in nicotinamide adenine dinucleotide (NAD)

scholarly journals The Stromelysin-1 5A/6A Promoter Polymorphism Is a Disease Marker for the Extent of Coronary Heart Disease

2002 ◽  
Vol 18 (3) ◽  
pp. 121-128 ◽  
Author(s):  
Adelheid Schwarz ◽  
Werner Haberbosch ◽  
Harald Tillmanns ◽  
Andreas Gardemann
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Total Sample ◽  
Promoter Polymorphism ◽  
Mean Values ◽  
Glucose Levels ◽  
Disease Marker ◽  
Triple Vessel Disease ◽  
Artery Disease ◽  
Glucose Plasma

Background.Matrix metalloproteinases, such as stromelysin-1, are implicated in the pathogenesis of coronary artery disease (CAD) and acute myocardial infarction (MI). A 5A/6A promoter polymorphism can regulate the transcription of the stromelysin-1 gene in an allele-specific manner. Evidence has been presented that the 6A allele is associated with the progression of coronary heart disease (CHD). In contrast, the 5A allele may be linked to the risk of MI.Results.To analyse the relation of the 5A/6A polymorphism with the risk and severity of CHD and the risk of MI, a case-control study of 515 healthy controls and 1848 participants who underwent coronary angiography for diagnostic purposes was conducted. In the total sample, the mean CHD scores—according to Gensini—were different between 5A/6A genotypes: 5A5A homozygotes had the lowest, 6A6A genotypes the highest and 5A6A heterozygotes intermediate scores. These differences were even more pronounced when the participants were restricted to individuals with a high coronary risk profile (high apoB levels, high Lp(a) levels, high glucose levels, combinations of either high apoB and Lp(a) levels or high apoB, Lp(a) and glucose plasma levels). Mean values were used as cut points for high-risk populations, respectively. In contrast, the 5A allele was not associated with the risk of CHD or MI. Even when angiographically controlled individuals without MI were compared with MI patients in subpopulations of participants with no, single, double and triple vessel disease, the frequencies of the 5A/6A and/or the 5A5A genotypes were not higher in each subgroup, respectively.Conclusions.The present results do not confirm an association of the 5A allele with the risk of MI, observed in another investigation, but strengthen the hypothesis of earlier studies that the 6A allele is a disease marker for progression of coronary heart disease. Further investigations should evaluate whether 6A allele carriers and especially 6A homozygotes might benefit from a more aggressive therapy against CHD progression.

scholarly journals GCKGene-Body Hypomethylation Is Associated with the Risk of Coronary Heart Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Limin Xu ◽  
Dawei Zheng ◽  
Lingyan Wang ◽  
Danjie Jiang ◽  
Haibo Liu ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Methylation Level ◽  
Cpg Island ◽  
Gene Body ◽  
Gene Body Methylation ◽  
Key Enzyme ◽  
Design And Methods ◽  
Pyrosequencing Technology

Objectives. Glucokinase encoded byGCKis a key enzyme that facilitates phosphorylation of glucose to glucose-6-phosphate. Variants ofGCKgene were shown to be associated with type 2 diabetes (T2D) and coronary heart disease (CHD). The goal of this study was to investigate the contribution ofGCKgene-body methylation to the risk of CHD.Design and Methods. 36 patients (18 males and 18 females) and 36 age- and sex-matched controls were collected for the current methylation research. DNA methylation level of the CpG island (CGI) region on theGCKgene-body was measured through the sodium bisulfite DNA conversion and pyrosequencing technology.Results.Our results indicated that CHD cases have a much lower methylation level (49.77 ± 6.43%) compared with controls (54.47 ± 7.65%,P=0.018). In addition,GCKgene-body methylation was found to be positively associated with aging in controls (r=0.443,P=0.010).Conclusions. Our study indicated that the hypomethylation ofGCKgene-body was significantly associated with the risk of CHD. Aging correlates with an elevation ofGCKmethylation in healthy controls.

Abstract 3683: Gender Difference in the Impact of Fasting Serum Glucose Level on Risk of Coronary Heart Disease: Korea Medical Insurance Corporation Study

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Song Vogue Ahn ◽  
Hyeon Chang Kim ◽  
Chung Mo Nam ◽  
Hyun Chul Lee ◽  
Il Suh
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Impaired Fasting Glucose ◽  
Fasting Glucose ◽  
Serum Glucose ◽  
Fasting Serum ◽  
Fasting Serum Glucose ◽  
Glucose Levels ◽  
Hazard Ratios ◽  
The Impact

Objective: Diabetic women have a greater relative risk of coronary heart disease than diabetic men. However, gender difference in the impact of blood glucose levels below diabetic range on risk of coronary heart disease is unclear. The aim of this study is to evaluate whether the association between nondiabetic blood glucose levels and the incident risk of coronary heart disease is different in men and women. Methods: We measured fasting serum glucose levels and other cardiovascular risk factors in 172,580 Koreans (108,461 men and 64,119 women), aged 35–59 years in 1990 and 1992. Our primary outcomes were hospital admissions and deaths from coronary heart disease in 11 year follow-up from 1993 to 2003. Cox proportional hazard models were used to estimate the hazard ratios for coronary heart disease according to the baseline fasting serum glucose levels, after adjustment for age, body mass index, blood pressure, total cholesterol level, and cigarette smoking. Results: During the 11 years, 3,769 coronary heart disease events occurred. Risk of coronary heart disease in men was significantly increased at fasting serum glucose levels of diabetic range (≥ 126 mg/dL), although risk of coronary heart disease in women was significantly increased from impaired fasting glucose levels ≥ 110 mg/dL. In fasting serum glucose levels ≥ 110 mg/dL, the hazard ratios for coronary heart disease incidence were higher in women than in men compared with women and men with fasting glucose levels <80mg/dL, respectively. There was no association between impaired fasting glucose from 100 to 109 mg/dL and risk of coronary heart disease neither in men nor in women. Conclusions: The stronger impact of fasting serum glucose levels on relative risk of coronary heart disease in women compared with in men was significant from impaired fasting glucose levels ≥ 110 mg/dL. Adjusted Hazard Ratios (HRs) for Coronary Heart Disease by Fasting Serum Glucose Levels

scholarly journals Association of liver X receptor α (LXRα) gene polymorphism and coronary heart disease, serum lipids and glucose levels

2014 ◽  
Vol 13 (1) ◽  
pp. 34 ◽  
Author(s):  
Yun-Fei Zhou ◽  
Jing Zhang ◽  
Zong-Xue Li ◽  
Jing-Li Miao ◽  
Qiao-Xiang Yin ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Gene Polymorphism ◽  
Serum Lipids ◽  
Liver X Receptor ◽  
Glucose Levels ◽  
Liver X Receptor Α

Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease

2006 ◽  
Vol 74 (3) ◽  
pp. 267-273 ◽  
Author(s):  
Stasia S. Reynolds ◽  
Lisa R. Yanek ◽  
Dhananjay Vaidya ◽  
Samia Mora ◽  
Taryn F. Moy ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Incident Diabetes ◽  
Normal Range ◽  
Premature Coronary Heart Disease ◽  
Glucose Levels
Sign in / Sign up

Export Citation Format

Share Document